Diamyd expects to begin reporting Phase III results in late spring 2011
Diamyd Medical’s President and CEO Elisabeth Lindner states in the CEO comments in today's quarterly report that the Company expects to begin reporting the results from the European Phase III trial in type 1 diabetes as planned in late spring 2011."When all patients have completed their 15-month visit in the European study, much work will lie ahead in the form of collecting the remaining documentation from the more than 60 participating clinics throughout Europe and from our central laboratory, which carry out all the analysis", says Elisabeth Lindner, CEO and President of Diamyd Medical. "